Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Adenovirus vector recombinant new coronavirus B.1.617.2 variant vaccine and application thereof

A mutant strain, adenovirus technology, applied in the field of bioengineering, can solve problems such as decreased protection rate

Active Publication Date: 2022-03-01
ACADEMY OF MILITARY MEDICAL SCI
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Considering that B.1.617.2 is widely prevalent in the world, and the protection rate of the new crown wild strain vaccine against B.1.617.2 virus infection is significantly reduced, the purpose of the present invention is to provide a new crown virus B.1.617.2 mutation strain of vaccines to deal with the continuous spread of mutant new crowns

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adenovirus vector recombinant new coronavirus B.1.617.2 variant vaccine and application thereof
  • Adenovirus vector recombinant new coronavirus B.1.617.2 variant vaccine and application thereof
  • Adenovirus vector recombinant new coronavirus B.1.617.2 variant vaccine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1: Preparation of recombinant new coronavirus B.1.617.2 variant vaccine using human replication-deficient type 5 adenovirus as carrier

[0031] 1.1 Antigen protein screening and design of new crown B.1.617.2 variant strain

[0032]In January 2021, before the large-scale outbreak of the new crown B.1.617.2 mutant strain in India, there was a small-scale epidemic in Indonesia. We selected the sample collected from Indonesia in January (GISAID Accession ID: EPI_ISL_1969244) as a template to obtain the Spike (S) protein sequence of the mutant strain. On this basis, in order to ensure the stability and integrity of the protein and improve the expression level, the protein structure was mutated. First, replace its original signal peptide with tissue plasminogen activator signal peptide (tPA), and replace 986-position lysine with proline, and replace 987-position valine with proline to improve S Protein stability and expression levels. In addition, arginines at posi...

Embodiment 2

[0042] Example 2: Evaluation of Immune Response of New Crown B.1.617.2 Variant Vaccine

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel crown variant vaccine taking human type 5 replication-deficient adenovirus as a vector. The vaccine takes E1 and E3 combined deletion replication-deficient human type 5 adenovirus as a carrier, and a novel coronavirus B.1.617.2 variant spike protein mutant coding gene (Ad5-nCoV-B.1.617.2) which is subjected to optimization design is integrated in a genome of the E1 and E3 combined deletion replication-deficient human type 5 adenovirus vaccine. The vaccine can effectively express protective antigen protein in host cells. The specific antibody reaction aiming at the B.1.617.2 variant can be excited by using the vaccine for single immunization. When the novel coronavirus vaccine is combined with a 2019 wild type novel coronavirus vaccine for use, a strong and broad-spectrum new coronavirus variant neutralizing antibody reaction can be stimulated after vaccine booster immunization, and the novel coronavirus vaccine has a remarkable application advantage, particularly has an outstanding advantage in heterotype booster immunization and coping with a new coronavirus B.1.617.2 variant epidemic situation, can be used as a vaccine candidate strain, and can be used for preparing a new coronavirus vaccine for preventing and treating the new coronavirus B.1.617.2 variant epidemic situation. The method is used for coping with continuously-spreading new crown variant epidemic situations.

Description

technical field [0001] The invention belongs to the technical field of bioengineering, and in particular relates to a recombinant novel coronavirus B.1.617.2 mutant strain vaccine. Background technique [0002] The new coronavirus is an RNA virus, which is very prone to mutations during the continuous transmission process, and naturally screens out the dominant mutant strains with enhanced transmission capabilities. B.1.617.2 (Delta, Delta) mutant strain samples were first collected from the United States in March 2020, and samples of this type of mutant strains were successively collected in South Africa, Indonesia, the United Kingdom and other places. After October 2020, the mutant strains Occurring in large numbers in India, the variant was identified as one of the drivers of the second wave of infections in India. In May 2021, the B.1.617.2 mutant strain began to spread rapidly around the world; in early July, the B.1.617.2 mutant strain had appeared in at least 98 coun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/165C12N15/50C12N7/01C12N15/861A61K39/215A61P31/14C12R1/93
CPCC07K14/005C12N7/00C12N15/86A61K39/12A61P31/14C12N2770/20022C12N2770/20034C12N2710/10021C12N2710/10022C12N2710/10043A61K2039/5256Y02A50/30
Inventor 陈薇王步森侯利华徐婧含吴诗坡张哲赵拯浩张金龙宋小红王玉东付玲陈旖
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com